American College of Cardiology (ACC)

The American College of Cardiology (ACC) is the primary U.S. medical society representing the interests of all cardiology subspecialities. The ACC is very active in setting guidelines for cardiac care, lobbying for supportive government policy and reimbursements, clinician education, managing several key cardiovascular registries and advocating for the transformation of cardiovascular care to improve heart health.

RSS icon
MitraClip vs mitral valve edge to edge repair (TEER).

VIDEO: MitraClip vs. surgical mitral valve replacement

Joanna Chikwe, MD, founding chair of the department of cardiac surgery at Cedars-Sinai Hospital, compares transcatheter edge-to-edge repair (TEER) to mitral valve surgery for primary mitral regurgitation.

April 7, 2022
Steven Nissen, MD, Cleveland Clinic, explains an ACC.22 late-breaking trials that uses an mRNA drug to greatly reduce lipoprotein A. #ACC22

VIDEO: Use of mRNA drug to lower lipoprotein(a) by up to 98%

Steven E. Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the Cleveland Clinic, was the lead author on the Apollo Trial, a late-breaking ACC.22 study evaluating the effectiveness of an mRNA drug to suppress lipoprotein(a).

April 7, 2022
The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

Renal denervation linked to significant blood pressure reductions after 3 years

An updated look at patients treated with Medtronic's renal denervation system was presented at ACC.22 and simultaneously published in The Lancet. 

April 6, 2022
ACC.22.jpg

TAVR vs. surgery, FFR-guided PCI and DCB safety: Day 3 at ACC.22

Read our in-person coverage of the final day of ACC.22.

April 4, 2022
Steven E. Nissen, MD, discusses his late-breaking clinical trial with panelist Vera Bittner, MD.

Cholesterol medications, flu shots and heart failure: Day 2 at ACC.22

Day 2 of ACC.22 was jam-packed with late-breaking clinical trials. Read our quick rundown of what researchers shared with the public for the very first time. 

April 4, 2022
ACC.22 kicked off on Saturday, April 2, in Washington, D.C.

Salt restrictions, PCI breakthroughs and a social media primer for cardiologists: Day 1 at ACC.22

Explore our on-the-ground coverage of the first day of ACC.22.

April 3, 2022
Cardiologist heart

Cardiology groups debut new heart failure guidelines ahead of ACC.22

The new recommendations went live just ahead of ACC.22. They can be read in full in the Journal of the American College of Cardiology, Circulation or Journal of Cardiac Failure.

April 1, 2022
stroke

Depression linked to a higher stroke risk among heart attack survivors

The new findings, based on data from nearly 500,000 patients, were presented during ACC.22.

April 1, 2022
Displaying 201 - 208 of 234
Design by Adaptive Theme